MarketPulse
B

$BNTX

7 articles found
0 positive
3 negative
4 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Anaveon Ag

Biotech Veteran Ramanayake Takes Helm at Anaveon as Immune Reprogramming Firm Pursues Clinical Trials

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.
PFENVSBNTXclinical developmentautoimmune diseases
BenzingaBenzinga··Erica Kollmann

BioNTech Stock Crashes 17.67% on Weak Guidance and Founder Exit Plans

BioNTech shares plummeted as the biotech firm issued lower 2026 revenue guidance and co-founders announced plans to exit by year-end 2026.
BNTXstock declinerevenue guidance
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

BioNTech Faces Shareholder Investigation Amid Losses and Founder Exodus

Law firm investigates $BNTX following €305M Q4 loss, plunging COVID vaccine demand, and planned founder departure, examining potential securities law violations.
BNTXfederal securities lawssecurities fraud investigation
BenzingaBenzinga··Vandana Singh

BioNTech Plummets 14% as Co-Founders Exit for New mRNA Venture

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.
BMYCELGrPFEMRNABNTXguidance reductionPhase 3 trials
BenzingaBenzinga··Vandana Singh

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.
MRNABNTXROIVABUSbalance sheet strengthmRNA technology
BenzingaBenzinga··Nabaparna Bhattacharya

Large-Cap Stocks Rally on Earnings Beat and Corporate Actions

Large-cap stocks rallied on strong earnings and corporate actions. First Majestic Silver led with 25% gains, joined by Moderna and Global Payments on positive results.
COINPAASFIGAGMRNA+6earningsFDA approval
BenzingaBenzinga··Vandana Singh

BioNTech Sues Moderna Over Patent Rights to Next-Gen COVID Vaccine

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.
PFEMRNABNTXintellectual propertymRNA technology